ICOS

Picarro Releases PI5310 Nitrous Oxide Gas Analyzer to Advance Atmospheric Research

Retrieved on: 
Thursday, April 4, 2024
Carbon, ICOS, Climate change, Greenhouse gas, PPT, Nitrous oxide, Calibration, Software, N2O, High, Cavity, CRDS, CO, Integrated Carbon Observation System, WMO, Enterprise, Cavity ring-down spectroscopy, Greenhouse, Carbon monoxide

SANTA CLARA, Calif., April 4, 2024 /PRNewswire/ -- Picarro Inc., a leading provider of gas concentration and stable isotope analyzers that empower the world with timely, trusted, and actionable data, today released the PI5310 Gas Concentration Analyzer. The new mid-infrared (mid-IR) analyzer delivers the industry's highest precision measurements of nitrous oxide (N2O) and carbon monoxide (CO) with the lowest drift. Precisely measuring these greenhouse gases (GHGs) is critical in atmospheric studies related to climate change, such as the World Meteorological Organization's (WMO) proposed Global Greenhouse Gas Watch (G3W). The G3W requires the individual model systems taking part in the program to deliver data on N2O abundances and net fluxes.

Key Points: 
  • The new mid-infrared (mid-IR) analyzer delivers the industry's highest precision measurements of nitrous oxide (N2O) and carbon monoxide (CO) with the lowest drift.
  • "With its industry-leading precision and minimal drift, the PI5310 analyzer is tailored for the most demanding greenhouse gas monitoring networks," said Joel Avrunin, Vice President of Environmental Business for Picarro.
  • "We're thrilled to introduce this state-of-the-art analyzer, further strengthening our suite of real-time monitoring solutions aimed at advancing crucial atmospheric research."
  • The PI5310 analyzer meets and exceeds the requirements of the WMO GHG compatibility goals and Integrated Carbon Observation System (ICOS) atmospheric station specifications.

Picarro Releases PI5310 Nitrous Oxide Gas Analyzer to Advance Atmospheric Research

Retrieved on: 
Thursday, April 4, 2024
Carbon, ICOS, Climate change, Greenhouse gas, PPT, Nitrous oxide, Calibration, Software, N2O, High, Cavity, CRDS, CO, Integrated Carbon Observation System, WMO, Enterprise, Cavity ring-down spectroscopy, Greenhouse, Carbon monoxide

SANTA CLARA, Calif., April 4, 2024 /PRNewswire/ -- Picarro Inc., a leading provider of gas concentration and stable isotope analyzers that empower the world with timely, trusted, and actionable data, today released the PI5310 Gas Concentration Analyzer. The new mid-infrared (mid-IR) analyzer delivers the industry's highest precision measurements of nitrous oxide (N2O) and carbon monoxide (CO) with the lowest drift. Precisely measuring these greenhouse gases (GHGs) is critical in atmospheric studies related to climate change, such as the World Meteorological Organization's (WMO) proposed Global Greenhouse Gas Watch (G3W). The G3W requires the individual model systems taking part in the program to deliver data on N2O abundances and net fluxes.

Key Points: 
  • The new mid-infrared (mid-IR) analyzer delivers the industry's highest precision measurements of nitrous oxide (N2O) and carbon monoxide (CO) with the lowest drift.
  • "With its industry-leading precision and minimal drift, the PI5310 analyzer is tailored for the most demanding greenhouse gas monitoring networks," said Joel Avrunin, Vice President of Environmental Business for Picarro.
  • "We're thrilled to introduce this state-of-the-art analyzer, further strengthening our suite of real-time monitoring solutions aimed at advancing crucial atmospheric research."
  • The PI5310 analyzer meets and exceeds the requirements of the WMO GHG compatibility goals and Integrated Carbon Observation System (ICOS) atmospheric station specifications.

CyberArk Announces 2023 Global Partner of the Year Award Winners

Retrieved on: 
Tuesday, February 13, 2024
Security, Technology, Other Technology, Software, Networks, Internet, CYBR, Cloud, Education, Partnership, Growth, Atos, ICOS, CGI, Kyndryl, Partner, Capgemini, Accenture, Software as a service, DTI, PwC, Computacenter, AWS, KPMG

CyberArk (NASDAQ: CYBR ), the identity security company, today announced the winners of its 2023 Global Partner of the Year awards.

Key Points: 
  • CyberArk (NASDAQ: CYBR ), the identity security company, today announced the winners of its 2023 Global Partner of the Year awards.
  • CyberArk’s partner program achieved strong momentum in 2023, marking the highest percentage of partner-assisted business to date.
  • The CyberArk Partner Network is one of the industry’s largest global networks of security-focused partners, with more than 1,300 global systems integrators (GSIs), managed service providers (MSPs), solution providers, strategic outsourcers, advisories and distributors, as well as global and regional marketplaces.
  • “Congratulations to all 2023 Partner of the Year winners!

Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Genetics, Health, Clinical Trials, Gene, Rheumatology, Patient, Inflammation, Synergy, Lupus, American College, CD28, SLE, ALPN, CD80, Alpine, ICOS, Autoimmunity, Immunoglobulin G, CD86, Pharmaceutical industry, Vaccine, Research

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
  • Acazicolcept target-related genes (ICOS, CD80, CD86) are upregulated in the T and B cells of SLE patients compared to healthy adults.
  • Acazicolcept reduces pathogenic hypergammaglobulinemia and glomerular IgG deposition in a mouse model of lupus.
  • Clinical investigation of acazicolcept for the treatment of SLE, such as in our ongoing phase 2 study, Synergy, continues to be supported.”

The IEEE International Roadmap for Devices and Systems (IRDS) Emerges as a Global Leader for Chips Acts Visions and Programs

Retrieved on: 
Tuesday, December 12, 2023
SCR, 3DIC, Ecosystem, METI, European Chips Act, Multilateralism, Balestra, ITRS, Organization, International, Provinces of Greece, LOS, TFRC, IRC, Society, Ministry, IRDS, TIA, Keio University, Nanoelectronics, Siemens Digital Industries Software, NIST, ICOS, MOU, Device, IEEE, NSTC, WSC, IRCS, Electronics, IEEE CS, TSMC, Faculty, IAC, Task force, Visiting scholar, Consumer electronics, Mobile phone, Science, System, Semiconductor

LOS ALAMITOS, Calif., Dec. 12, 2023 /PRNewswire/ --The broad utilization of the IEEE International Roadmap for Devices and Systems (IRDS) is influencing the various Chips Acts worldwide.

Key Points: 
  • LOS ALAMITOS, Calif., Dec. 12, 2023 /PRNewswire/ --The broad utilization of the IEEE International Roadmap for Devices and Systems (IRDS) is influencing the various Chips Acts worldwide.
  • Initiatives in Europe, Japan, and the US are engaging the IRDS roadmap for guidance as their activities develop, said Tom Coughlin, President of IEEE.
  • IEEE International Roadmap for Devices and Systems maps the future for microelectronics industry.
  • The SiNANO Institute , European Academic and Scientific Association for Nanoelectronics and the Systems and Devices Roadmap of Japan (SDRJ) are founding members of IRDS.

Xencor Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ICOS, AACR, CD28, European Alliance of Associations for Rheumatology, Cancer, ENPP3, American Association for Cancer Research, Janssen, TACSTD2, NMOSD, Research, CLDN6, Part, Genentech, Antibody, AstraZeneca, CEACAM5, ASCO, Congress, Patient, STEAP1, Ipilimumab, Colorectal cancer, Vir, EULAR, Cytokine, PD-1, Neuromyelitis optica spectrum disorder, Ovarian cancer, European Alliance, IND, Tumor microenvironment, Roche, Vaccine, Pharmaceutical industry, Cryptocurrency, Video game, EU, MorphoSys, Astellas Pharma, Rheumatology, Alexion, Ravulizumab

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
  • In the first quarter of 2023, Xencor earned $10.5 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Revenues for the first quarter ended March 31, 2023 were $19.0 million, compared to $85.5 million for the same period in 2022.
  • ET (1:30 p.m. PT) to discuss the first quarter 2023 financial results and provide a corporate update.

Semiconductor Assembly And Packaging Equipment Market Overview: Major Drivers, Top Players, And Strategies - By The Business Research Company

Retrieved on: 
Thursday, March 16, 2023
EVS, ICOS, International Energy Agency, EV, KLA, BE, Applied Materials, Growth, Semiconductor, Big data, Artificial intelligence, AI, Kronos

LONDON, March 16, 2023 /PRNewswire/ -- As per The Business Research Company's Semiconductor Assembly And Packaging Equipment Global Market 2023, the global semiconductor assembly and packaging equipment market size will grow from $10.4 billion in 2022 to $11.8 billion in 2023 at a compound annual growth rate (CAGR) of more than 13%. The global semiconductor assembly and packaging equipment market size is then expected to grow to $18.7 billion in 2027 at a CAGR of more than 12%.

Key Points: 
  • LONDON, March 16, 2023 /PRNewswire/ -- As per The Business Research Company's Semiconductor Assembly And Packaging Equipment Global Market 2023, the global semiconductor assembly and packaging equipment market size will grow from $10.4 billion in 2022 to $11.8 billion in 2023 at a compound annual growth rate (CAGR) of more than 13%.
  • The global semiconductor assembly and packaging equipment market size is then expected to grow to $18.7 billion in 2027 at a CAGR of more than 12%.
  • The rise in demand for electric vehicles (EVs) across the world will contribute to the growth of the semiconductor assembly and packaging equipment market in the forecast period.
  • Companies in the semiconductor assembly and packaging equipment market are focusing on innovating new products with advanced semiconductor packaging techniques.

Semiconductor Assembly And Packaging Equipment Market Overview: Major Drivers, Top Players, And Strategies - By The Business Research Company

Retrieved on: 
Thursday, March 16, 2023
EVS, ICOS, International Energy Agency, EV, KLA, BE, Applied Materials, Growth, Semiconductor, Big data, Artificial intelligence, AI, Kronos

LONDON, March 16, 2023 /PRNewswire/ -- As per The Business Research Company's Semiconductor Assembly And Packaging Equipment Global Market 2023, the global semiconductor assembly and packaging equipment market size will grow from $10.4 billion in 2022 to $11.8 billion in 2023 at a compound annual growth rate (CAGR) of more than 13%. The global semiconductor assembly and packaging equipment market size is then expected to grow to $18.7 billion in 2027 at a CAGR of more than 12%.

Key Points: 
  • LONDON, March 16, 2023 /PRNewswire/ -- As per The Business Research Company's Semiconductor Assembly And Packaging Equipment Global Market 2023, the global semiconductor assembly and packaging equipment market size will grow from $10.4 billion in 2022 to $11.8 billion in 2023 at a compound annual growth rate (CAGR) of more than 13%.
  • The global semiconductor assembly and packaging equipment market size is then expected to grow to $18.7 billion in 2027 at a CAGR of more than 12%.
  • The rise in demand for electric vehicles (EVs) across the world will contribute to the growth of the semiconductor assembly and packaging equipment market in the forecast period.
  • Companies in the semiconductor assembly and packaging equipment market are focusing on innovating new products with advanced semiconductor packaging techniques.

Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder

Retrieved on: 
Thursday, March 9, 2023
Ocean Biomedical, Colorectal cancer, Neoplasm, Breast cancer, Survival, Ovarian cancer, Skin cancer, Brown University, Cancer, Biology, HIV disease progression rates, Research, Patient, PTEN, Fibrosis, ICOS, Lung cancer, Prostate cancer, Kidney cancer, CTLA4, Antibody, Cluster, Apoptosis, Journal, PD-1, RI, NSCLC, CD28, B7-1, Composition, Prognosis, B7-2, Pharmaceutical industry, Medical imaging, Vaccine, Melanoma, Medicine, Immunology, CHI3L1, Frontiers, MD, Glioblastoma

In his talk, Dr. Elias focused on his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1).

Key Points: 
  • In his talk, Dr. Elias focused on his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1).
  • He also shared details of his novel therapeutic discoveries that show the efficacy of monospecific and bispecific antibodies against CHI3L1 and PD-1 as therapies for non-small cell lung cancer, and glioblastoma multiforme.
  • Ocean Biomedical is currently working to move these antibody therapeutic discoveries towards Phase 1 clinical trials.
  • In his recent talk, Dr. Elias shared details of his team’s discoveries of the role CHI3L1 in regulating primary and metastatic lung cancer, glioblastoma multiforme, and broader oncogenic pathways.

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers

Retrieved on: 
Monday, January 30, 2023
B7-1, Antibody, Fibrosis, Metastasis, Skin cancer, Melanoma, Cluster, Journal, PD-1, Large-cell lung carcinoma, Cancer, Biology, NSCLC, B7-2, RI, Outline, Lung, PTEN, Patient, ICOS, CD28, Apoptosis, Glioblastoma, CTLA4, Neoplasm, Research, Vaccine, Medical imaging, Immunology, CHI3L1, Medicine, Frontiers

Providence, RI and New York, NY, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today the discovery of a second major anti-tumor pathway and therapeutic approach that targets CTLA-4, inhibiting the metastasis of malignant melanoma cells to the lung using a novel bispecific antibody approach. This major regulating mechanism discovery, recently published in Frontiers in Immunology, by Ocean Biomedical’s Scientific Co-founder and Brown University’s Emeritus Dean of Medicine and Biological Sciences, Dr. Jack A. Elias, builds on his team’s prior discoveries that target Chitinase 3-like-1 (CHI3LI) and its role in inhibiting T-cell proliferation. Additionally, this promising research reveals a third anti-tumor pathway targeting T-cell co-stimulation using the inducible co-stimulator (ICOS) and its ligand ICOSL, and Cluster of Differentiation 28 (CD28) and its ligands B7-1 and B7-2. Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.

Key Points: 
  • Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.
  • “If you control CH3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.
  • Malignant melanoma, a very serious skin cancer with a 22.5% five-year survival for patients with Stage IV disease, can metastasize to other organs.
  • We look forward to working with Ocean Biomedical to bring all of these therapies to patients, for the long-term shareholder value and the continued advancement of medical science.”